Please assess the completion status of the following clinical trial:

Trial Title: Papillary Serous Carcinoma of the Endometrium

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient must undergo surgical staging within 8 weeks of study entry.~2. Patients with mixed histology tumor that include a papillary serous component are eligible.~3. Only patients with non-measurable disease can be entered.~4. Patients may not have had previous chemotherapy or radiation therapy.~5. Patients must have an estimated life expectancy of 12 weeks or greater.~6. Patients must have a Zubrod performance status of less than or equal to 2.~7. Patients must have adequate bone marrow, renal and hepatic function: with white blood count (WBC) greater than or equal to 3000; Absolute neutrophil count (ANC) greater than or equal to 1500; Platelets greater than or equal to 100,000; glutamic-pyruvic transaminase (SGPT) less than or equal to 2 times the upper limit of normal; Total bilirubin less than or equal to 2.5mg/dl.~8. Patients must sign an institutionally approved consent form~Exclusion Criteria:~1. Previously treated papillary serous carcinoma with either chemotherapy or radiation therapy.~2. Newly diagnosed papillary serous carcinoma of the endometrium, Stage IIIB-IV (patients with disease outside the pelvis).~3. Patients who have a history of other malignancy, with the exception of non-melanomatous skin cancer, unless in complete remission and off all therapy for that disease for a minimum of 5 years.~4. Patients with a Zubrod status of 3 or greater.~5. Patients with an active infection.~6. Patients with serious intercurrent medical illness.~7. Patients with a recent (within 6 months) history of congestive heart failure, unstable angina or myocardial infarction.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Paclitaxel (Taxol) + Pelvic Radiation (Type: EXPERIMENTAL): Paclitaxel (Taxol) 50 mg/m\^2 intravenous (IV) weekly over 1 hour for 5 weeks. Radiation therapy to the pelvis daily for 25 treatments.~Both radiation therapy and paclitaxel chemotherapy on Day 1 or 2, followed by radiation alone for four days, repeated every week for a total of 5 weeks, giving a total dose of 45 Gy with external beam radiation to pelvis and 5 courses of paclitaxel 50 mg/m\^2. Four-six weeks after pelvic radiation completed, 4 additional courses of paclitaxel 135 mg/m\^2 alone given every 21 days. Vaginal apex boost given either with last 3 external beam treatments or after external beam radiation completed for additional 3 days. No chemotherapy given with vaginal apex boost.

Based on this trial design, predict the completion outcome and termination type (if applicable).